Compare PROF & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PROF | TNXP |
|---|---|---|
| Founded | N/A | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.2M | 197.9M |
| IPO Year | N/A | N/A |
| Metric | PROF | TNXP |
|---|---|---|
| Price | $6.60 | $19.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | $11.00 | ★ $70.00 |
| AVG Volume (30 Days) | 100.8K | ★ 802.7K |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,297,000.00 | $10,299,000.00 |
| Revenue This Year | $64.23 | $14.79 |
| Revenue Next Year | $113.06 | $933.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 67.94 | N/A |
| 52 Week Low | $3.76 | $6.76 |
| 52 Week High | $8.36 | $130.00 |
| Indicator | PROF | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 57.49 | 59.63 |
| Support Level | $6.09 | $15.10 |
| Resistance Level | $7.04 | $16.18 |
| Average True Range (ATR) | 0.42 | 1.39 |
| MACD | 0.02 | 0.74 |
| Stochastic Oscillator | 70.27 | 93.12 |
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.